Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC - Episode 4
Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
Related Content: